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INTRODUCTION 
 
                                  
  
 Human   Immunodeficiency  Virus  ( HIV )  infection  is  
spreading through  the  world  in  a  rampant  manner currently.    HIV 
manifests  from  an  asymptomatic  carrier  state  to  AIDS.      Multiple organs  
are  affected  by  the  invading  organism. Renal involvement in  HIV  patients  
occurs  due  to disease per se or  due  to  associated  problems like 
opportunistic infections, septicemia,  hypovolemia and drug  toxicity1,2.    HIV 
infection  was recognized in 1980 and the renal  pathology  of   
immunodeficiency  virus  was  recognized  in  1984  in USA .Renal disorders 
are encountered at all stages of  HIV  infection and  range  from   fluid  and  
electrolyte  imbalances  commonly  seen  in  hospitalized  HIV  infected 
patients to HIV associated nephropathy (HIVAN)  which  can  progress  
rapidly  to  End  Stage Renal Disease [ESRD] 3.         
                 
            HIV  related  renal disease have become the  third leading cause  
of  end stage renal disease4. Overt proteinuria has been encountered  in  43-
47%  of  AIDS  patients 5and also low  molecular weight proteinuria noticed in 
over 80%  of  asymptomatic  HIV seropositive   patients 6.       
 
 
  
 
       Microalbuminuria  is an  independent and  earliest  marker of  
renal damage,   and  may  be  the  first  sign  of  silent  kidney disease. The  
currently  available kidney function test do not identify early kidney 
involvement.  Hence  the present study was undertaken to confirm  or  refute  
the  earlier  observations  on  microalbuminuria  in HIV and AIDS cases. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
AIM & OBJECTIVES 
 
 
 
 
1. To estimate microalbuminuria in HIV and AIDS patients  
 
 
 
2. To correlate the micro albumin level with CD4 cell count. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
REVIEW OF LITERATURE 
 
   
MICROALBUMINURIA 
DEFINITION:- 
 Microalbuminuria      has    been    defined    as   albumin excretion  of   
20  to 200  µg/minute  ( OR )  30  to  300  mg/day  in  a 24 hours urinary 
sample,  anything  above  this  level  of  excretion  is  called  
macroalbuminuria.   Microalbuminuria  can  also  be defined in terms of the 
urinary albumin to creatinine  ratio greater  than  30 mg/g in the first voided  
sample in the morning. 
               The details are  depicted  in  the  table  given  below. 
Table -1    
 
 
Definition of abnormality in albumin excretion 
 
Category 
 
 
24-hrs        
Collection 
( mg/24hrs ) 
 
Timed 
Collection 
( µg/min ) 
 
Spot 
collection 
(mg/g cre) 
 
Normal 
 
< 30 
 
< 20 
 
< 30 
 
Microalbuminuria  
30 – 299 
 
20 - 199 
 
30 – 299 
 
Clinical 
albuminuria 
 
>300 
 
>200 
 
 
>300 
 
 
  
PATHOPHYSIOLOGY OF MICROALBUMINURIA 
 The    glomerular  capillary  wall   ( GCW )   provides  a  barrier  
to  filtration  of   large  macromolecules.   The   GCW   has   3 components  
i) Endothelium of the capillary 
ii) Basement membrane 
iii) Epithelial cells (podocytes). Surrounding  the  outer  surface of  
the  capillary  basement  membrane . 
Together,    these make up the filtration barrier,   which despite the three 
layers, filters  several  hundred  times  as  much  water and solutes as the usual 
capillary membrane. The  barrier to filtration  is  provided  by  2 mechanisms:  
size selectivity  and  charge selectivity.      
 
Filterability   of   substances   by   glomerular   capillaries    decreases   
with   increasing molecular weight. 
 Filterability of selected substances is shown in Table2. 
 
Table- 2 
 
 
Substance Molecular 
Weight 
Filterability 
Water 18 1.0 
Sodium 23 1.0 
Glucose 180 1.0 
Myoglobin 17000 0.75 
Albumin 69,000 0.005 
  
     Size  selectivity   is  a  feature  of  the   size  of   the   pores  in   
the components of   the  barrier.   The  endothelial  cells  have  fenestrations 
with an approximate  radius of  40nm and, as such, do not provide an effective 
barrier to albumin, which has a radius of  3.6 nm. The GBM  has  pores  with  
a  radius  of  4 nm.   Between  the  foot  processes  of epithelial cells, a thin 
membrane  called  a slit  diaphragm provides a barrier to filtration.  The  pores 
in the slit membrane  are  the same size  as  those  in  the GBM.  The  GBM  
and  slit  diaphragms are,  therefore,   the major components of size selectivity. 
  Charge selectivity    is   provided   by   negatively  charged 
anions, such   as   heparan  sulphate  proteoglycan ,      which  repel  negatively  
charged molecules  such  as albumin.   These anions are present on both 
endothelial cells and  the  GBM,  which thus provide charge selectivity.    The 
negative charge on the GBM  also may be important for adhesion of epithelial 
cells , such  that  loss of  the  negative  charge  may  result  in  disruption  of  
the epithelial cell barrier,  which in turn contributes to increased permeability  
to  macromolecules such  as albumin ( due  to  loss  of  size  selectivity ).     
When  damage  to  the  basement membrane or components of  the  glomerular 
epithelial  cell  occur,      often  the  first manifestation  is   the  appearance  of   
plasma  proteins  in  the  urine. 
 
  
 Because albumin is  the  major circulating  protein  in plasma  and  is  
relatively  close in size to that of the size selectivity barrier,    its  appearance  
in  the  urine is   the  most  sensitive  indicator  of  damage  or  disruption  of  
the   glomerular filtration barrier.  
HUMAN  IMMUNODEFICIENCY VIRUS 
                   The origin of HIV is unclear.  The most likely scenario is that  
HIV was  introduced  into  human  from  another  primate in  sub Saharan  
Africa. 7  
 
ETIOLOGY AGENT :-  
 The  etiologic  agent  of   AIDS   is    Human   Immuno   
deficiency Virus1  ( HIV-1 )  &  HIV-2   belongs   to   the  family  of   human   
retroviruses  (Retroviridae )  and  the  subfamily  of   lentiviruses . 
 
MORPHOLOGY OF HIV :- 
 Electron  microscopy shows  that the  HIV  is  spherical  
enveloped  virus, about  90-120 nm  in size. The nucleocapsid has an outer 
icosahedral shell  containing   numerous   external   spikes   formed   by  the  
two  major  envelope proteins, the external gp 120 and  the transmembrane gp 
41, and  an  inner  cone   shaped  core ,  enclosing the ribonucleproteins. 
  
 
ELECTRON MICROSCOPIC VIEW OF HIV  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ATTACHMENT AND ENTRY 
 The replication cycle of HIV begins with  the  high affinity 
binding  of  the  gp 120 protein via  a  portion of  its v1 region near  the N  
terminus to its receptor on the host cell surface , the CD4 molecule . It   is   
also  expressed   on  the   surface   of    monocytes / macrophages  and   
dendritic / langerhans  cells .   Once  gp  120  binds to CD4,    the  gp  120  
undergoes a conformational change that facilitates binding  to  one  of  a  
group of  co – receptors .   The  two  major  co–receptor of  HIV -1 are CCR5  
and  CXCR4. 
REVERSE TRANSCRIPTION AND INTEGRATION 
                 Following  binding  of  the  envelop  protein  to the CD4  
molecule,   the  virus  is “uncoated “  and  the viral  RNA is converted  into  
complementary  DNA  (C-DNA)   by  vireon – associated   reverse  
transcriptase enzyme .    The  C-DNA is transported to the host cell nucleus 
and  eventually gets  incorporated  into  the  host  cell  chromosomes.  Virus 
specific  integrase enzyme is essential for this function.   
TRANSCRIPTION , TRANSLATION AND REPLICATION 
           The  integrated DNA is transcribed into messenger RNA ( mRNA )  
which comes out  into the cytoplasm  and  viral  proteins  are  synthesized  
using  protein  synthesizing  machinery and  raw material from the host cell .   
Some of the viral proteins are synthesized as polyproteins that are eventually  
cleared  by  protease  enzyme. 
  
 
REPLICATION CYCLE OF HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATURATION AND RELEASE 
   Newly   synthesized   progeny   RNA   and   proteins  are 
packaged together and the newly formed virus particles are released from  the 
infected cell by the “budding” process . 
 
HIV GENOME 
                  HIV-1 has the following genes,     gag  –  encodes  the proteins 
that form the core of  the virion.  Pol – encodes  the  reverse  transcriptase  
enzyme.    env – for envelope  glycoproteins. It also contains  atleast  six other  
genes  tat ,  rev,  nef, vif, vpr and vpu,  which code for proteins involved in the 
regulation of gene expression.  
   
                  The major difference between the genomes of  HIV 1 and HIV 2  
is  the  fact  that   HIV 2  lacks  the  vpu  gene and  has a vpx  gene not 
contained in HIV-1. 
 
EPIDEMIOLOGY:- 
                   India is now considered the country with largest number of 
infected persons  in  the  world 8.   India  alone  accounts for 4 million cases.  
The spread mainly  occurs  through  heterosexual  route. 
 
  
 
 
PATTERN OF HIV TRANSMISSION 
 
Table - 3 
 
 
Type of exposure % of global 
total 
Efficiency per      
single Exposure 
 
% of India total
Sexual inter course 
       Vaginal 
        Anal 
 
 
       70-80% 
       5-10% 
 
        0.1-1% 
        0.1-1% 
 
        83.3% 
 
 
 
Perinatal 
 
5-10% 
 
30% 
 
2% 
 
 
Injection drug use 
 
5-10% 
 
0.5-10% 
 
3.8% 
 
 
Blood 
Transfusion 
 
3-5% 
 
>90% 
 
3.5% 
 
 
Health care 
Needle sticks 
 
 
<0.01 
 
 
<0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MOLECULAR EPIDEMIOLOGY OF HIV 
 According to DNA sequence data  HIV-1, can be divided into 
three  major groups . 
1. Group ‘m’ (major),   which contains ten genetically distinct sub types   
- A to J.                                                                    
2.  Group ‘O’  (outlier),   which contains various heterogeneous viruses . 
          3.  Group  ‘N’  (Cameroon type) 
         In  addition,    there are  at  least  5  sub types  of   HIV-2,    it is 
the predominant virus in West Afican countries and has also been reported in 
India.    Importance of  molecular epidemiology is that it can  offer  clues as 
to how the virus spreads between the regions and continents. 
PROGRESSION OF ILLNESS:- 
 Average  period  to  develop  AIDS  is  8 – 10 yrs. The 
documented cytopathic effect is  50-80 cells/µL per  year.  About  5-10%  of  
infected people progress to AIDS with in 2-3 years, they are called rapid 
progressors. About 5% of infected people do not progresses to AIDS even 
after 10 years, they are called long term non progressors.  
The reasons being 
1.  Mutant nef gene of HIV 9 
2.  Defective   CCR-5  co binding  protein  on  macrophage  due  
to genetic abnormality in the patient 10 
 
  
CLASSIFICATION 
 Revised  classification  system   for  HIV  infection   and  expanded   
AIDS surveillance case  definition for adolescents and adults  (CDC –Atlanta)- 
1993. 
 
Table- 4 
 
 
 
CLINICAL CATEGORIES 
A B C 
 
CD4 + Cell count    
(per microlitre)      
Conditions 
Asymptomatic, 
acute primary 
infection or PGL 
Symptomatic 
but not A or C 
conditions 
 
AIDS indicator 
>500 A1 B1 C1 
200 – 499 A2 B2 C2 
<200 A3 B3 C3 
 
 PGL  -  Progressive Generalized Lymphadenopathy 
 
HIV infected persons classified in A3, B3, C1,C2,C3 are AIDS cases. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1993 AIDS surveillance case definition CDC Atlanta:  
Category A: 
          One or more of  the following conditions in an  adolescent  ( >13 years 
of age )  or  adults 
 
       1.  Asymptomatic HIV infection  
2.  Progressive Generalized Lymphadenopathy  
3. Acute (Primary)  HIV  infection  with  accompanying illness or 
history of acute HIV infection. 
 
Category B:  
  Consists of  symptomatic conditions in an HIV  infected 
adolescent  or  adult  that  are not included in clinical category‘C’ and that  
meet  at least one of the following criteria.  
 
a) The conditions are attributed to HIV infection or indicative of  a 
defect in cell mediated immunity (CMI).  
b)    conditions  are  considered  by   physician   to  have  a clinical  
course  or  to  require  management  that  is  complicated   by  HIV 
infection.  
 
  
Examples include  
1.  Bacillary angiomatosis  
2.  Vulvo vaginal candidiasis (Persistent ,  frequent  or  poorly  responsive  
to therapy ) oral candidiasis                  
3.  Cervical dysplasia, cervical carcinoma in situ 
4.  Constitutional symptoms lasting more than one month 
5.  Oral hairy leukoplakia 
6. Herpes zoster involving at least 2 distinct episodes or more than one  
dermatome 
7.  Idiopathic thrombocytopenic purpura  
8.  Listeriosis  
9.  Pelvic inflammatory disease  
10.  Peripheral neuropathy  
 
Category ‘C’: 
AIDS Indicator Conditions:  
1.  Candidiasis of the bronchi,  trachea or lungs       
2.  Oesophageal candidiasis   
3.  Cervical cancer – invasive 
4.  Coccidioidomycosis - disseminated  or  extrapulmonary  
5.  Cryptococcosis – extra pulmonary  
 6.  Cryptosporidiosis – Chronic intestinal ( > one month duration)    
7.  Cytomegalovirus disease  (other  than  lung,  spleen and  nodes) 
8.  CMV  retinitis  ( with  loss  of  vision )  
9.  HIV  related  encephalopathy  
10. Herpes simplex – chronic ulcer,  bronchitis,  pneumonia  or 
oesophagitis 
11. Histoplasmosis  –  disseminated  or  extra  pulmonary  
12. Isosporiasis  –  chronic  intestinal  ( >  one  month  duration )  
13. Kaposi’s  sarcoma  
14. Burkitt’s  lymphoma 
15. Immunoblastic  lymphoma   
16. Primary  brain  lymphoma  
17. MAIC, M.kansasii infection– disseminated or extra pulmonary  
18. M.tuberculosis  –  any   site  
19. Mycobacterium  other  species  or  unidentified  species - disseminated      
      or extrapulmonary  
20. Pneumocystis  Jiroveci  pneumonia 
21. Recurrent  pneumonia  
22. progressive  Multifocal  Leukoencephalopathy  
23. Salmonella  septicaemia  –  recurrent  
24. Toxoplasmosis  of  brain  
25. Wasting  syndrome  
  
 
RENAL INVOLVEMENT IN HIV AND AIDS 
 
Historical perspective 
                Rao et al11,  in  1984  described  focal  and segmented 
glomerulosclerosis  in  nine patients with AIDS and nephritic syndrome .  The 
changes were similar to heroin induced nephropathy, the  progression  to end 
stage renal disease in these patients was much more rampant. In the  same year  
pardo et al 12,  reported a variety of glomerular changes seen at autopsy in 
patients with AIDS. Since then many  reports  have  validated  renal   
involvement   in   HIV  infected population  and  a  wide  spectrum  of   renal  
syndromes   have   been reported . 
 
Spectrum of renal diseases  
           The  renal  manifestation  of  HIV  infection  occur commonly  
during  all  stages of  infection3.  Renal  manifestations of HIV infection occurs  
in  6 – 10 %  of  HIV seropositive individuals.13 A  wide  spectrum  of  renal 
syndromes has been associated with  HIV infection. 
 
 
 
  
Overview of HIV related renal diseases     
 Acute renal failure 
 Pre renal   
                     ♦ Hypovolemia      
                        [ Diarrhoea, vomiting, bleeding, pancreatitis ] 
                     ♦ Hypoalbuminemia    
                        [ severe malnutrition , cirrhosis ]             
Renal    
            Mostly induced by drugs    
                     ♦ Acute tubular Necrosis                              
                        [Aminoglycosides, amphotericin B, foscamet, pentamidine, 
    contrast based dyes,  rhabdomyolysis ]                        
  ♦ Allergic interstitial nephritis       
                        [protease inhibitors,  trimethoprim /sulfamethaxazole,   
     phenytoin cephalosporins ] 
  ♦ Crystal deposition [ protease inhibitors,  sulfadiazine, acyclovir]        
   Post Renal   
                    ♦ External obstruction    
                       [Tumor, prostate hyperplasia, urethral obstruction,  
      retroperitoneal fibrosis ] 
           ♦ Internal obstruction [crystal deposition, blood clots,   
   tumor  lysis ] 
  
 
  B) Chronic Renal failure  
          Focal glomerulosclerosis  ( classic HIVAN )  
          Immune complex disease   
                    ♦ IgA nephropathy   
                    ♦ mixed sclerotic immune complex nephropathy   
                    ♦ proliferation glomerulo nephritis 
 Microangiopathies 
  ♦ Hemolytic uremic syndrome 
  ♦ Thrombotic thrombocytopenic purpura 
 Renal amyloidosis 
 Renal   paranchymal    invasion    by   malignancies 
            [ lymphoma  , Kaposi’s sarcoma ] 
    
C) Fluid and electrolyte disorders 
 Hyponatremia due to 
  ♦ fluid loss 
  ♦ SIADH 
  ♦ Infection – toxoplasmosis , tuberculosis , pneumocystis 
  ♦ Adrenal insufficiency 
  
  
 
 Hyprerkalemia due to                                                              
  ♦ Adrenal insufficiency 
  ♦ Hyporeninemic hypoaldoteronism 
  ♦ IDDM [ pentamidine induced,  pancreatic cell dysfunction ] 
  ♦ severe ARF 
 
 Hypokalemia due to 
  ♦ GI losses 
  ♦ Renal potassium wasting 
 
 Metabolic alkalosis due to 
  ♦ Upper GI loss 
  ♦ Hypokalemia 
 
 Metabolic acidosis due to 
  ♦ Renal failure 
  ♦ Septic shock 
  ♦ Diarrhoea 
   ♦ Drug induced interstitial nephritis 
 
  
ACUTE RENAL FAILURE  
 The  fundamental etiology and mechanisms involved in acute 
renal injury in HIV patients are generally the same as in non HIV patients. 
Acute  deterioration  in  renal  failure  may  be  thought  of  as  pre  renal, 
intrinsic to  renal  tissue  and  post  renal.   In over whelming  number  of 
patients with ARF,  pre  renal etiology is noted.  Pre renal causes  of ARF 
include  hypovolemic  states   due   to   profuse   vomiting,   diarrhoea  and 
infections, sepsis, excessive  and  life  threatening  bleeding . 
 
 Intrinsic   ARF    in    HIV    infected    patients   may   be   due    
to hypovolemic, sepsis, shock and use of nephrotoxic agents for therapeutic 
and  diagnostic purposes. Rhabomyolysis, azotemia, use of NSAIDS, 
hemolytic uremic syndrome (HUS) and thrombocytopenic purpura (TTP) are 
the other causes of ARF . 
 
 Post renal acute renal failure may be either due to extra renal or 
distal obstruction,   intrinsic  obstruction  may  also  lead  to  post  renal ARF.   
Out flow obstruction , retroperitoneal fibrosis and crystalluria may contribute 
to post renal ARF. Indinavir , sulfadiazine and acyclovir have been  implicated  
in  crystalluria . 14 
 
  
Acute renal failure classified as mild ARF and severe ARF 
Mild ARF :-   
                  Defined as a peak sr.creatinine of  >2 mg/dL and occurs upto 20%  
of  hospitalized  HIV  infected  patients  . 15  
Severe ARF :-   
                 Defined as a peak sr.creatinine of  > 6  mg/dL seen  in  75%  of  
cases.   Severe renal failure in HIV infected patients may be associated with  
terminal conditions  in  which acute dialysis would be inappropriate. 
  
FLUID  & ELECTROLYTE DISORDERS  :- 
 Among  the electrolyte  abnormalities observed  in  HIV patients ,  
hyponatremia  and  hyperkalemia  are  most  significant.  
Hyponatremia:-  
¾ It is the most common, reported 30 – 60% of hospitalized   symptomatic 
HIV  and  AIDS  patients . 
¾ Severe hyponatremia in HIV infected patients 16 indicate poor   
prognosis     
¾ Volume  depletion  due  to  diarrhoea or vomiting  is  the  usual cause  
of  hyponatremia  present at the time of hospital  admission.         
¾ Excess  body  water is attributed either to hypovolemia with physiologic             
stimulation of ADH, administration of hypotonic fluids  or  the SIADH.                      
  
SIADH is the likely culprit in those who  develop  hyponatremia  during 
hospitalization 15 . 
¾ SIADH  is  usually associated with common pulmonary and intracranial       
disease such as pneumocystis pneumonia,  toxoplasmosis,  tuberculosis. 
¾ AIDS patients have a high incidence of  adrenal abnormalities. Adrenal 
pathology particularly CMV infection is found common in patients who 
have died from  AIDS.17   Other  pathologic   lesions   that   have  been  
noted frequently include hemorrhage toxoplasma infection, 
Cryptococcus, mycobacterium tuberculosis ,   MAC ,    infiltration  with  
Kaposi’s  sarcoma  and   lymphoma . 
 
    Hyperkalemia :-    
        Occurs as a result of the effect of  
¾ High dose  of trimethoprin –  sulfamethoxazole or  IV pentamidine.  The 
underlying  mechanisms  with  both  drugs consists of inhibition of 
distal nephron  sodium  transport,   leading  to  a  decrease  in distal  
potassium secretion. 1  Trimethoprin shares structural  similarity with the 
potassium sparring diuretic triamterene. 
¾ Hyperkalemia  and hyponatremia may also be manifestation of  minerlo 
corticord  deficiency  due  to  adrenal insufficiency or the syndrome of  
hyporeninemic   hypoaldosteronism .18 
  
¾ A  systemic  abnormality  in  potassium equilibrium, which favours  the 
development   of   hyperkalemia   by   a  mechanism  unrelated  to               
renal potassium excretion,  has been identified in HIV infected patients             
individuals. 19 
 
III CHRONIC RENAL FAILURE 
a) HIV associated nephropathy ( HIVAN ) 
           HIVAN represents a major complication of HIV infection. The  
evolution  of  HIVAN  is  the  development  of  nephrotic syndrome initially 
and progress to end stage renal disease in most patients.20 
 
            HIVAN  has  become  the  most  common  single diagnosis in 
HIV  infected  patients  with  renal  insufficiency. The true prevalence of  
HIVAN  is  not  known.  HIVAN  is  common  in  urban  centers  with  
prevalence of  about 10%. The  geographic distribution of  HIVAN is not 
uniform and depends  on  specific risk factors which include race,  gender and 
drug use. 
 HIVAN  is  recognized  throughout the spectrum of HIV disease .    
It can be first manifestation of HIV infection or even precede detection of  
HIV andibodies.21 
  
  
 HIVAN  is 7–10 times more common in men, men comprises 80  
to  90 %  of  cases 22,  Black  men  have increased  risk.  30 – 60 %  of  people  
with HIVAN have a history of Intra Venus Drug Users (IVDU).23  The 
remainders are either homosexual or originate from regions where HIV 
infection is endemic. In approximately 10% patients no specific risk factors 
for HIV can be identified.  
 Unfortunately, most patients who develop HIVAN do not have 
early signs or symptoms that would provide a clue to this diagnosis prior  to  
the  onset  of  progressive  nephropathy. 
  
PATHOGENESIS :- 
            The pathogenesis of  HIVAN has been studied intensely over the  
past  15  years.  The  question  in  the  pathogenesis  of  HIVAN  is whether  
the  disease  can  be attributed  to  direct  viral  effect  or to HIV related  
changed  on  the  cytokine  milieu.  HIVAN is caused by HIV gene expression  
in  renal  tissue,  resulting in injury of glomerular and tubular epithelial cells. 
            Early  studies  using  in situ  hybridation to a  C-DNA  nuclei acid  
probe  found  the  HIV  genome in  tubular and glomerular epithelial cells  in   
patients with  HIVAN. Patients with immune mediated glomerulonephritis  or  
HIV  infected  patients  with  no renal disease had less cellular involvement.  
 
  
 
 Since  HIV  proliferation appears to be the major determinant of 
cytotoxicity, factors that precipitate viral replication with in the kidney could  
explain  the  sudden  onset  of  the  disease.  HIV  proliferation is regulated by 
at least two genes nef  and vif with opposing action. Minor mutation  in  
either  of  these could lead to rapid viral proliferation and death of the host 
cell. Concomitant infection with viral hepatitis, syphilis or CMV, could  
induce  HIV  replication. CMV  may  promote  viral proliferation,  through  a  
mechanism  that is dependant on tumor necrosis factor  ( TNF ). 24 
 
  HIV  is a  potent  stimulation of transforming growth factor β a 
cytokine strongly implicated in the development of fibrosis. The  transgenic  
mouse  model  (Tg 26)  suggests  that activation of  the cytokine  could  will  
be the basis for the extensive interstitial fibrosis and glomerularsclerosis  that 
are the hall marks of HIVAN.25 
 
           HIV DNA and protein markers specific for HIV has been 
demonstrated in  tubular epithelium, glomerular epithelial cells and mesangeal  
cells by a variety of  techniques in vitro and in renal biopsy tissue of HIV 
patients.26  
 
            In  transgenic mouse model ( Tg 26 ) HIV-1 envelope ( gp 41 and 
gp 120 ) and regulatory genes are expressed  but  gag and  pol  genes are  
deleted  to  render  the  virus  non  infections. These  mice  develop a 
syndrome  closely  resembling  HIVAN.27     Kidneys  were  transplanted 
between normal and transgenic mice.  HIVAN then developed in the non 
transgenic littermates, where as the normal kidneys remained disease free 
when  transplanted   into   transgenic littermates.  This  study  provides 
evidence  that  HIVAN  is caused  by a direct HIV gene expression rather than  
the  systemic  effects  of  HIV  infection . 28 
 
          HIV  infection  may  involve  epithelial  cells  from  multiple 
segments  of  the  nephron,  including  proximal  tubule,  thick  ascending loop  
of  Henle  and  collecting  duct.  This  pattern of  involvement  may explain 
the tubular dilatation seen in kidney biopsy  specimens of patients with 
HIVAN .29 
 The kidney  also  seems  to  be  a reservoir for HIV.  Despite 
undetectable  viral  levels in  the  serum, a case report described a patient who  
continued  to  express  HIV  in  renal  epithelial  cells determined by RNA   in   
situ  hybridation.30   There  is  also  compelling  evidence that active    
replication   of    HIV   occurs   in   kidney  epithelium, possibly producing  
HIV  strains in the kidney microenvironment, that differ from HIV circulating 
in the blood. This  suggest  that  kidney may serve as a viral  reservoir  
 harboring  HIV  strains  that  have  evolved  under  tissue, specific  selection  
pressures.31 
 
HISTOPATHOLOGY :- 
           HIVAN  is associated  with  characteristic glomerular  tubulo 
interstitial  and  ultra  structural  lesions.  Autopsy data demonstrates that 90%  
of  patients with  the  clinical  diagnosis  of  HIVAN have focal and segmental   
glomerulosclerosis.16  
           Histopathologically, classic HIVAN is a collapsing form of  focal 
segmental glomerulosclerosis with podocyte hyperplasia and 
dedifferentiation, associated with severe tubulopathy which is characterized 
by tubular apoptosis, microcytes and interstitial fibrosis.32 
 
 Light microscopic features :- 
 ♦ Collapsing   focal  segmented  glomerulosclerosis  or  
     masangial   hyperplasia. 
♦  Cystic  tubular  dilatation 
♦  Interstitial  edema   
  ♦  Cellular   infiltration  by  lymphocytes  or  monocytes 
♦  Dilated   degenerating   proximal   tubules   filled   with  
eosinophilic material,  possible representing cast  formation  
in situ. 
 
 Electron microscopy features:- 
 The presence of numerous tubuloreticular inclusions with in 
endothelial cells is important finding in HIVAN. Finding numerous 
tubuloreticular  inclusions  in capillary endothelial cells in a patient 
with FSGS   prompts some pathologists to request HIV antibody 
testing [ HR enuka ,   Brigham and women’s hospital ,  personal 
communication, 1994 ] . 
 Although  renal  tissue may stain  for  IgM,  c1q,  c3  and  kappa or  
lamda  light  chains  in  areas of  focal  sclerosis, immunologic                     
mechanisms are probably not central to genesis of HIVAN.33                                  
 
 CLINICAL PRESENTATION 
                  ♦   Proteinuria  but  no  hematuria  on  urine analysis  
♦ High grade proteinuria usually in nephrotic range(>3.5 
gms/day) Proteinuria is the hallmark of HIVAN. Over all 
microalbuminuria is  seen  in  ~20% of untreated  HIV infected 
patients,  significant proteinuria  is  seen  in   2%.34 
INVESTIGATION:- 
 ♦ Urine   analysis  often  reveals  severe  proteinuria  with  oval  
      fat bodies and frank  lipiduria,  Broad waxy casts also seen.                         
  ♦ Microalbuminuria  is  seen  in  ~20%  of  untreated  HIV 
    patients.                         
 ♦ Azotemia, proteinuria or both are the presenting feature in  
    >90%  of  HIV  infected  patients.  
  ♦ Renal ultrasound: shows normal or enlarged renal silhouette 
   with increased  echo genicity . 
 
Renomegaly may be the result of   
a) in  sufficient  time  for  global  sclerosis and fibrosis in the 
rapid progression  of  renal  disease. 
 
b) marked  dilation of  the  tubules with  numerous  microcyts,    
in contrast to the tubular collapse frequently seen in other 
forms of chronic  renal  injury  and  interstitial  edema.35 
♦ Renal Biopsy :- confirm the clinical diagnosis of HIVAN. 
 
MANAGEMENT:- 
               The  rate of progression from the initial presentation to ESRD  
was  2.5 months in the pre HAART.  HAART therapy has been shown to 
retard the progression of renal disease in persons with HIVAN.36 
Available treatments are 
  ♦ Anti retroviral therapy 
  ♦ steroid treatment 
  ♦ ACE inhibitors 
  
 
ART  :- 
 There  have  been  case  reports  of  dramatic improvements in renal 
function  with  initiation of combination ART30 but no prospective studies 
have shown a benefit in the course of HIVAN.  Most reports experience is 
with  zidovudin  may  slow or  reverse  the  rapid  deterioration associated with  
HIVAN.37 
 
Steroid treatment :- 
  There   is   20   to   40   response   rate   to corticosteroids therapy. 
Prednisolone  60 mg/day for 2 to 11 weeks leads to a significant reduction in  
sr.creatinine  and  24 hrs  urine  protein  excretion 38  due to reversal of 
interstitial    inflammation   and   80%   reduction   in  risk  of  progressive 
azotemia.39 
 
ACE inhibitors: 
  Angiotension  II  increases  the  cellular  synthesis of   
transforming  growth    factor   beta   ( TGF β )   which   has   been   implicated  
in  the pathogenesis  of  HIVAN,  ACE  inhibitors  are  effective  in slowing  
the progression  of  renal  insufficiency by reducing production TGF β in both 
humans and  HIV  transgenic  mice.  Studies  suggest  that ACE inhibitors       
 Initiated early may offer renal survival benefits in HIVAN.40  Renal biopsy 
should be offered to patients as the treatment implications and prognosis vary  
according  to  the  biopsy  results .  
 
 Risk factors for progressive renal disease include 
  ♦ CD4 cell count <200 cells / µl. 
  ♦ Detectable HIV RNA level  
  ♦ Hypertension 
  ♦ Hypo albuminemia 
  ♦ Elevated Sr.creatinine41 
 
II ) Immune  complex Disease 
  HIV associated  immune  mediated  renal disease in the most 
common glomerular disease found on renal biopsy in series reported from Italy 
and France.22 
          Important  forms of  immune  complex GN in HIV infections are 
 i)  IgA nephropathy  
 ii) Hepatitis C virus related renal disease. 
 
            HIV  has  been implicated as a stimulus for immune complex 
formation   in   IgA   nephropathy,  immune   complexes   with    antigen have  
 been  identified  in  the  circulation  and  renal  tissue eluates of HIV infected  
patients with  IgA  nephropathy and with other immune complex GN.42 
 
Other patterns of glomerular involvement are 
  ♦ membranous nephropathy 
  ♦ membrane proliferation GN 
  ♦ mesangial proliferation GN 
  ♦ Diffuse proliferation GN 
  ♦ cresentic GN 
 
III)  Microangiopathies associated with HIV infection may present as 
hemolytic uremic syndrome or thrombotic thrombocytozenic purpura . 
        Other renal diseases reported less commonly 
 ♦ Minimal change disease 
  ♦ Amyloidosis 
  ♦ Tumor invasion of the kidneys 
 
END STAGE RENAL DISEASE 
 HIVAN  has become the third leading cause of ESRD among 
African Americans aged 20 – 64 years.43  Black patients infected with HIV are  
at  risk  for  the development of  HIV ESRD, irrespective of mode of viral  
acquisition.44 
 Management options for these patients include  
 ♦ Hemodialysis 
 ♦ Peritoneal dialysis 
 ♦ Transplantation 
MICROALBUMINURIA IN HIV AND AIDS PATIENTS 
           Microalbuminuria   is   the   earliest   marker   for   the   renal 
involvement.   Overall,  microalbuminuria  is seen  in  ~ 20% of  untreated 
HIV  infected  patients.34  Significant proteinuria is seen in  2%. Various 
studies  were  conducted  to  find out the incidence of microalbuminuria in 
HIV  infected  patients.  
     LUKE  et al,45   noticed  abnormal  urinary  levels  of  micro 
albumin in  19.4% of HIV positive patients.  Micro albumin levels were not 
correlated  with  race, sex, risk factor of  AIDS, disease history or concurrent  
drug  therapy .                
                 In contrast, urinary micro albumin levels were correlated  
with CD4 T cell, suggesting an association between AIDS progression  and  
microalbuminuria . 
 Busch  et al,46 study also found that albuminuria occurred 
exclusively  with  CD4  T  cell  counts  below  200 / mm3.      
               Despite of  available literature on this area, no such work has been  
carried  out  in  this part of the country with local AIDS cases due to inherent  
constraints.  This  study  attempts  to  fill up  the  gap. 
  
   MATERIALS  AND METHODS 
 
 
 Setting :  This study was carried out at  
                       Government Rajaji Hospital,  Madurai  Medical College, 
                       Madurai.          
Collaborating 
Department  : Anti retroviral therapy centre / Sexually transmitted disease                           
                         Dept and Nephrology department Madurai Medical College,                         
                         Madurai. 
 
Study Design   :  Cross sectional study 
Period of study:  Dec 2004 to Dec 2005 
 
Sample size  & Selection of study subjects:  
                     The  study  was conducted in HIV positive patients who were  
attending  the  ART  clinic,  Government Rajaji  Hospital,  Madurai. 300 HIV  
positive  patients  were  screened,  of  which,  60  patients who satisfied  the 
inclusion criteria included in the study and further evaluated. 20 healthy 
individuals (age and sex matched) were kept as control. 
Inclusion criteria :    
 Adult  male  &  non  pregnant female  HIV  infected 
AIDS patients before ART therapy. 
  
 
Exclusion criteria :   
Children, overt renal disease, Diabetes mellitus , systemic   
hypertension, collagen vascular disease, cardiomyopathy, urinary  tract   
infection  and  Nephrotoxic  agents used patients. 
 
Ethical issues :         
 The  study  group  thus  identified  by  the  above  criteria   
(inclusion  & exclusion)  are  first briefed about the nature of the study . 
Willing participants  were  taken  up  after  getting  a  written   informed 
consent  from  them. 
 
Materials :     
                Total of 60 cases who satisfied  the inclusion & exclusion criteria 
above were taken up for the study .  Twenty age and sex matched subjects 
were kept as control. 
 
Conflict of interest : There was no conflict of interest . 
 
Financial support :   NIL. 
 
  
 
 
 
 
   LIMITATION  
 
1. Due to technical and financial constraints, only 60 cases and 20  
     controls could be measured for microalbuminuria. 
2. Only microalbuminuria  & 24 hours urinary protein was measured.      
3. Renal biopsy was not attempted due to ethical reason. 
4. Long term follow up was not attempted. 
5. Effect of  ART  on  microalbuminuria  was  beyond   the  purview   
of  the  study.  
6. Viral load could not be estimated due to constraints. 
 
 
 
 
 
 
 
  
METHODOLOGY 
   Selected  socio-demographic , clinical , and  laboratory data were  
elicited  from  the patients and controls  and recorded in a proforma.  
 
I . Socio- demographic data:   
                    Age 
  Sex 
II . Clinical data : 
  Clinical examination 
III . Laboratory data : 
    albumin                    TC 
 Urine   sugar    DC 
    deposit    Hb % 
 
  Bl.sugar 
  Bl.urine 
            Sr.creatinine 
      Na+ 
                    Sr.electrolyte         
           Cl- 
 
  
 
Microalbuminuria & Urine albumin / creatinine ratio :-  
               Here the 24 hours urine was collected. It is measured by radio 
immuno  assay for microalbuminuria & Urine albumin / creatinine ratio. 
 
24 hours urinary protein 
 
CD4 count : 
The standard method for enumerating CD4 T cells uses a flow 
cytometer.  A computer calculates the number of CD4 T cells by analyzing the 
size of the cell and which of the antibodies it has been tagged with.  The 
overall process is called Fluorescence Activated Cell Sorting (FACS) 
 
ECG 
USG abdomen 
 
IV . Statistical analysis :                     
               Data   was   entered   in   Microsoft  excel  spread  sheet   and 
analyzed, statistically   using   standard   statistical   software. Student ‘t’ test 
and chi-square test were applied for significance. Significance was considered  
if  the  ‘p’ value  was  below  0.05.                                  
  
 
 
 
 
RESULTS 
 
         The total number of subjects included in this study was 80. Among 
these 80 subjects, 60 were case (HIV and AIDS patients) and 20 were controls.  
Table- 5 
 
Distribution of case & control : Age wise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This table compares the mean age of cases and controls. There is no 
significant difference between the cases and controls with respect to age.   
 
 
         Cases 
 
        Control 
 
Age group 
 
  NO 
 
   % 
 
   NO 
 
    % 
 
     21 – 30 
 
   22 
  
   36 
  
    9 
      
     45 
      
     31- 40 
  
   30 
   
   50 
      
    9 
 
45 
      
    41- 50           
 
   8 
  
   14 
  
    2 
 
10 
 
     
    Total 
  
   60 
 
   100 
    
    20 
      
     100 
    
    Mean age 
  
   33.57
  
    31.8 
 
  
      SD 
 
   5.94 
  
    6.87 
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Table -6 
Distribution of cases and control : gender wise 
 
 
 
                                                          
 
  
  
 
 
 
 
 
 
 
 
 
 
The table  compares  the  sex  distribution  in cases and  controls .  There 
is no significant difference in the distribution with respect to sex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cases Controls  
Sex  
NO 
 
% 
 
NO 
 
% 
 
Male 
 
 
31 
 
51.7 
 
10 
 
50 
 
Female 
 
 
29 
 
48.3 
 
10 
 
50 
 
Total 
 
 
60 
 
100 
 
20 
 
100 
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Table -7 
 
Case distribution in relation to CD4 count. 
 
 
 
 
CD4 count 
 
No of cases 
 
Group A 
CD4 < 200 
 
 
30 
 
Group B 
CD4 >200 
 
 
30 
 
 
The cases  are equally divided  into  2 groups,  based  on  CD4  counts,  
in patients  group A  has  CD4< 200,   group B  has  CD4 > 200,   each group 
consists of 30 members. 
 
 
 
 
 
 
 
  
 
Table- 8 
Distribution of cases in relation to CD4 Count :   Age & Gender wise 
 
 
 
Group A 
CD4 <200 
Group B 
                CD4>200 
 
AGE 
 
Male Female Male Female 
 
21-30 
 
 
7 
 
4 
 
2 
 
9 
 
31-40 
 
 
7 
 
7 
 
12 
 
4 
 
41-50 
 
 
1 
 
4 
 
2 
 
1 
 
Total 
 
 
15 
 
15 
 
16 
 
14 
 
    p value for Sex  =  0.7961 
    p value for Age  =  0.6164 
This table shows there is no significant difference in the CD4 count with 
respect to age and gender. 
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Table - 9 A 
     Microalbuminuria between cases and controls 
 
     Cases       Controls  
  No   %   No     % 
 
Microalbuminuria
 
  16 
 
 26.6 
 
  Nil 
     
    0 
 
Normal 
  
  44 
 
 73.4 
 
  20 
 
   100 
 
Total  
 
 60 
 
 100 
 
 20 
 
   100 
 
 
This table shows 26.6% of cases had microalbuminuria and none of the 
controls  had  microalbuminuria. 
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Table - 9 B 
       
 
  
 
  
 
 
 
  
 
                                            Using   students ’t’ test = 6.31 
                      P value < 0.000001. 
 
The mean microalbuminuria is 31.14mg/day (SD  34.34) in cases and 
2.93 mg/day (SD 2.68) in controls. P value < 0.000001, this clearly shows 
microalbuminuria level is significantly higher in HIV and AIDS patients. 
 
 
 
 
 
 
 
 
   Cases     Controls 
 
Mean 
  
  SD 
 
Mean 
 
  SD 
 
 
 
Microalbuminuria 
 31.14 34.34  2.93   2.68 
  
 
Table – 10 
Distribution of microalbuminuria in cases  :-   Age & Gender wise 
 
 GROUP A 
CD4 <  200 
GROUP B 
CD4 >  200 
Age Male Female Male Female 
21-30 3 1 - 1 
31-40 3 5 - - 
41-50 1 1 1 - 
Total 7 7 1 1 
 
 In group A, with CD4 count < 200, Microalbuminuria is seen in 14 
cases, comprising 7 male and 7 female patients. 
 In Group B, with CD4 count > 200, Microalbuminuria is seen in 2 cases, 
comprising 1 male & 1 female patient. 
 The table shows microalbuminuria not affected by the gender.  
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Table - 11 
Distribution of cases and controls with respect to biochemical 
Parameters 
 
     Cases    Controls  
Biochemical 
parameter 
 
 
 Mean
 
 SD 
 
Mean 
 
 SD 
    
   
    P value 
 
   Bl.sugar 
 
 85.77 
 
7.07
 
 87.89 
 
7.79
 
     0.3045 
    
   Bl.urea 
 
 29.33 
 
8.89
  
 24.42 
 
4.03
 
     0.0012 
   
Sr.creatinine 
 
 0.99 
 
0.39
 
 0.85 
 
0.11
 
     0.0146 
 
    Sr.Na+ 
 
138.88
 
3.39
 
140.56
 
3.35
 
     0.0666 
 
    Sr K+ 
 
  4.10 
 
0.47
 
 4.21 
`  
     0.2594 
 
 
There  is  statistically  significant  difference  between  cases  and  
controls  with respect  to  blood  urea  and  Sr.creatinine  which   can   be  
attribute to  the renal involvement. But with respect to Bl.sugar, Sr.sodium, 
Sr.pottassium, there is no statistically significant difference between cases and 
controls. 
 
 
 
 
 
 
  
 
 
 
 
 
Table - 12 
      Microalbuminuria in relation to CD4 counts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This      table   shows   statistically   significant   increase  in the  
prevalence  of  microalbuminuria   with  decrease in the CD4 count. Out of  30  
cases  in  group A who had  CD4 count <200,  microalbuminuria  is  seen  in  
14 cases . In group B who had CD4 count >200, microalbuminuria is seen only 
in 2 cases.  
 
 
 
 
 
 
CD4 count 
 
Microalbuminuria
 
    Normal 
 
CD4 < 200 
(Group A) 
 
            14 
 
       16 
 
CD4 > 200 
(Group B) 
 
             2  
 
       28  
  
 
 
 
 
 
Table -13  
  Urine albumin / creatinine ratio among case and controls 
 
 
        Cases 
 
          Controls 
 
 
 
 
 
  
 Mean 
 
    SD 
 
  Mean 
 
     SD 
 
Urine Al/cr 
Ratio 
 
 
  39.6 
 
   51.89 
 
   10.14 
 
     1.64 
 
 
 
    
                                 P < 0.000001 
 
The  mean  urine  albumin / creatinine  ratio  is  39.6 mg/g ( SD  51.89 ) 
in cases and  10.14 mg/g  ( SD  1.64 ) in controls .  P value is  < 0.000001,    it 
indicates statistically   higher  significant  difference  between  cases  and  
controls    with respect to urine albumin creatinine ratio. 
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 Table -14 
Distribution of cases and controls in relation to 24 hours urine protein 
  
 
        Cases 
 
        Controls 
 
 
 
 
 
 
 Mean 
 
   SD 
 
 Mean 
 
   SD 
 
24 hours 
urine 
protein 
 
 
 
184.50 
 
 
 
 
 129.69
 
 
  93.05 
 
 
 10.12 
 
 
    P < 0.000001 
The  mean  urine  24  hours  protein is  184.50 mg/day  ( SD  129.69 )   
in  cases and  93.05 mg/day ( SD 10.12 ) in controls.  P value is < 0.000001,   
it indicates there is a statistically higher significant difference between cases 
and controls with respect to 24 hours urine protein. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 Table – 15 
Overt  Proteinuria in cases with respect to CD4 count 
 
 
 
 
 
This  table  shows that  in  group A  with CD4  count  < 200,   
microalbuminuria occurs in 14 cases, of which  6  patients ( 42.8 % ) had  
overt proteinuria.   Where  as  in group B with CD4  > 200, microalbuminuria  
occurs  in 2 cases,  of which 1 patient  had overt proteinuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 count 
 
Microalbuminuria
Overt 
Proteinuria 
 
 
 CD4 < 200 
 
 
            14 
 
          6 
 
 CD4 > 200 
 
            2 
 
          1 
  
DISCUSSION 
 
 HIV  infection  is the pandemic of modern society.  Renal 
disorders are encountered at all stages of HIV infection.3 
 
 Microalbuminuria is  the  earliest  marker of the renal 
involvement, microalbuminuria  is  seen  in  approximately  20%  of  untreated  
HIV  infected patients.34 
 
 Winston JA et al 43   noted   HIVAN   has  become  the third 
leading cause of ESRD among African Americans aged 20-64 years. 
 
 Luke DR et al, 45   study  observed  that  micro albumin levels 
were not  correlated with  age, sex.     In our study also,  microalbuminuria 
levels were not affected by age and sex.   
 
              The  prevalence  of  microalbuminuria  in  HIV  and  AIDS 
patients differ in various studies.    Luke DR et al,45  study  noted  19.4% of  
patients  had  abnormal   levels  of  microalbuminuria.  Kimmel PL et al ,47    
study showed microalbuminuria  in  20  to 30%  of  HIV  patients .  
 
     
      In our study,  the prevalence of  microalbuminuria was found to  
be  26.6% .    The  mean  microalbuminuria  value  was  31.14  mg/day ( SD 
34.34 )  among  cases  and  2.93 mg/day  ( SD 2.68 )  among  controls. P value 
is < 0.000001. It indicates statistically  highly  significant  difference  in  cases 
and controls with respect to microalbuminuria. 
 
 Kimmel PL et al,  Umana WO et al 48 noticed that,  the prevalence  
of   an   increased   urinary  albumin / creatinine   ratio  was  29.8%  in  the  
HIV  infected  patients.   In Buch 46  HW et al study,  the prevalence rate  was  
13.4% .  In our study the urinary albumin / creatinine ratio was 26.6% in  HIV 
and  AIDS  patients.    The mean urine albumin / creatinine ratio  is  39.6 mg/g  
( SD 51.89 )  in cases  and  10.14  mg/g ( SD 1.64 ) in  controls .   P  value  is  
< 0.000001,   it   indicates   statistically   highly significant difference  in  cases 
and controls with respect to urine albumin / creatinine ratio. 
 
            Several    studies   have   suggested    that   abnormality  of  
protein excretion, without  frank  nephrotic  syndrome  is  common  in   HIV  
infected populations.   In  Agaba EI et al,49  proteinuria  was  detected in 25.3% 
of HIV patients. In Cravley ST et al,50 study the prevalence of asymptomatic 
proteinuria  was  14%  and   the  presence of  proteinuria was not correlated 
with viral load .  
   
 
                   Varma  PP  et al,51  study showed overt proteinuria was detected in 
17.6%  of   HIV  patients.    In  Gardner  et  al,52  overt proteinuria  was  
present  in 11.2%  of  HIV seropositive women.   In our study, 11.6% of HIV 
seropositive  patients  had  Overt proteinuria .  
 
   In our study, 7 patients had overt proteinuria out of 16 
microalbuminuria  patients (43.75%). Luke DR et al,45    study  showed  overt 
proteinuria  in  7  out  of  14  microalbuminuria patients(50%).  
 
              Various  studies  show  that  there is  a  strong  correlation  
between  CD4 count and microalbuminuria level.  Szczech LA et al 41,  Busch 
HW et al 46  and  Atta  MG  et al53  studies  also  confirmed  that,   
microalbuminuria is seen in exclusively with CD4 count below 200/mm3.  
 
 In  our  study , 16 out of  60 patients had elevated urinary levels  
of  micro albumin, of  which  14  patients  found to have CD4 count  
<200/mm3. 
 
 
 
  
 
 In our study revealed abnormalities of  Sr.Creatinine in 4 male 
and  4  female  patients.   Of   which  7  patients who had   elevated   creatinine  
were  found to have CD4 count < 200/mm3.    
 
 Though  there was biochemical evidence of  mild  renal  failure,   
they did  not   reveal   any   symptomatology  related  to  glomerular or   
interstitial  involvement.     Thus  this  study  revealed  that  HIV infected   and  
AIDS  individuals  may  have  asymptomatic  renal  involvement. 
 
    No electrolyte abnormalities were seen in our study.  How ever  the  
review  of  literature  showed  that  the  commonest  fluid  and  electrolyte 
abnormalities seen in HIV and AIDS cases is hyponatremia. 
 
                 Behar  DM et al 54  and  Winston  JA  et al,43  studies show that  
type  of   renal  involvement  varied   in  different  geographic  regions.   For 
instance,  in  US  there  was  remarkable  differences  for  the   geographic  
distribution  of  HIVAN.   In  this  group,  patients with heavy proteinuria 
developed progressive renal  disease.  South  Indian  population,    have  some  
similarities  as  black population in renal involvement.   
 
    
 
 Gardner, Lytt I et al,52  showed  proteinuria or elevated 
sr.creatinine   in    HIV   infected   women  were  associated  with  an increased  
risk  of  death   after  controlling  the  other risk factors.  Hence HIV infected 
patients have to be closely monitored for their renal function and  for  
microalbuminuria.    
 
This will help to identify 
a)   The triggering factor 
b)   The progression of renal involvement  
c)   To minimize the renal complication by early                    
                             intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
    SUMMARY 
 
 
 
                      The  present  study  was aimed  to study the microalbuminuria 
level  in  HIV seropositive  patients, and  also  to  find   out  its association 
with  CD4  counts. With rigid criteria 60 HIV seropositive cases and 20 
controls were selected. The controls were matched for age and  sex  compared  
to cases. There  were  31  males  and  29  females  in  the  case  group  and  10  
males  and  10  females in control group. 
 
            This study projects  high prevalence of microalbuminuria (26.6%)  
in HIV and AIDS patients. The mean microalbuminuria value was 31.14 
mg/day  (SD34.34)  among the cases  and 2.93 mg/day ( SD 2.68 ) among  the  
controls .  
 
 This     study   showed   the   urinary  albumin/creatinine  ratio  
was 26.6%  in  HIV and AIDS patients .   The  mean albumin/creatinine ratio 
is  39.6  mg/g in cases  and  10.14 mg/g  in controls.   In our study overt 
proteinuria present in 11.6%  of  HIV seropositive patients. 
 
 
  
 
 Microalbuminuria   levels  were  specifically  co related  with  
CD4  counts.  In this study  noted 14 patients out of 16 microalbuminuria cases 
found to have CD4 count <200/mm3. 
 
 The   present  study  revealed  abnormalities  of  Sr.creatinine  in  
8 patients , of which 7 patients  were  found  to  have  CD4  count <200/mm3.  
 
 Therefore   urinary  screening   for   microalbuminuria  in  HIV 
and   AIDS  patients  may  help  to  identify  renal  involvement  and  to 
minimize  the  renal  complication  by  early intervention and avoidance of  
nephro  toxic drugs in management. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
 Both  sexs  are equally affected.    Microalbuminuria  levels  had  no cor                 
- relation with the gender and age. 
 
 Microalbuminuria was significantly elevated in HIV and AIDS cases, it  
was seen  in  26.6% of  cases .  The  mean  microalbuminuria value was 
31.14 mg/day  in cases and 2.93 mg/day in controls.   
 
 The   prevalence  of    urinary  albumin / creatinine  ratio  was 26.6%  in              
HIV and  AIDS  patients.  The  mean  urine albumin / creatinine  ratio is              
39.6 mg/g  in cases and 10.14  mg/g in controls . 
 
 The  microalbuminuria  levels  were  specifically  correlated  with  CD4              
counts.      14  out  of  16  HIV  and  AIDS  patients  were found to have  
CD4 count <200/mm3. 
 
 Sr.creatinine  level is elevated in  8  patients,   of which 7 of the patients             
with  elevated  creatinine  were found to have CD4 count <200/mm3.  
 
 Overt proteinuria is present in 11.6 % of HIV seropositive patients.  
     
 Sr. sodium,  potassium are not altered in the study groups. 
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 PROFORMA 
 
 MICROALBUMINURIA IN HIV & AIDS  PATIENTS   
 
    NAME   AGE  SEX  OCCUPATION 
 
    ADDRESS    IP.NO : 
 
COMPLAINTS 
 
  
  HISTORY  OF  PATIENTS  ILLNESS: 
 □  Loss of appetite & weight  □   Leg swelling 
  □   Diarrhea     □ Facial puffiness 
  □ Vomiting     □ Hiccough 
  □ Fever      □ Haematuria 
□   Cough with expectoration           □ Head ache              
 □  Frequency of micturition   □ Chest pain 
  □ Oliguria  
 
HISTORY OF PAST ILLNESS:- 
□  Old PT &  treatment with ATT        □DM  □ Renal disease  
□ IHD   □ CCF □Jaundice □Blood transfusion   
□  Any other (specify) 
 
PERSONAL  H/o:- 
□ Smoking   □ Alcholic   
□ Sexual promiscuity □ Marital status 
□ Drug addition/abuse 
 
 
 
 GENERAL EXAMINATION:- 
  Height    Weight  
 
  PR:-    BP:- 
 □  Aneamia  □  Jaundice  □ Clubbing 
 □  Paedal edema □  Lymphadenopathy 
 
SYSTEMATIC EXAMINATION:- 
  RS 
 
  CVS 
 
  ABDOMEN 
 
    CNS 
 
INVESTIGATION:- 
  URINE -  Albumin      Bl.Sugar 
-  Sugar    Bl.urea 
-  Deposit    Bl.Creatinine 
 
     Sr.Eletrolytes  Na+ 
                                                                           Cl- 
Urine albumin & creatitinine  ratio     
 
MICRO ALBUMIN     
 
24 hrs urinary protein 
Sero positivity  HIV 1 □Reactive  CD4 count 
         HIV 2 □Non reactive DC,TC,HB% 
 
ECG 
 
USG Abdomen. 
 
 
 
 
 MASTER CHART 
S.No Age Sex CD4 CD8 CD4/CD8 
ratio 
Sugar Urea Creatinine NA+ CL- Micro 
albumin 
Urine 
Al/cr ratio
24 hrs urine  
protein 
1 45 F 586 1095 0.54 80 18 0.7 138 3.8 2.5 10.5 125 
2 40 M 339 586 0.58 92 18 0.7 136 3.9 1.8 9.2 130 
3 35 F 792 1215 0.65 76 28 0.6 138 3.3 6 8.3 50 
4 31 M 145 476 0.30 86 24 0.8 140 4.2 28 19 256 
5 28 F 964 630 1.53 95 23 0.7 138 4.5 2.5 16.5 136 
6 25 M 64 1029 0.06 82 38 1.2 138 4.3 44 76 345 
7 35 F 40 343 0.12 78 40 1.4 145 3.8 48 62 280 
8 37 F 256 585 0.16 80 22 0.6 140 4.6 18 22 126 
9 42 M 438 1523 0.28 88 21 0.7 136 4.5 14 11 125 
10 30 M 172 560 0.31 90 31 0.7 143 5.2 28 18 150 
11 34 F 198 720 0.3 76 27 0.6 136 3.8 26 20 172 
12 31 F 195 >2000 <0.10 70 32 0.8 136 3.8 46 68 260 
13 38 F 204 1127 0.18 76 24 0.7 139 3.2 10 16 88 
14 30 F 757 1388 0.55 82 26 0.8 136 4.2 13 12 102 
15 37 M 253 1895 0.13 80 28 0.9 138 4.6 12 18 60 
16 29 F 374 >2000 <0.19 92 27 0.7 135 4.8 26 24 116 
17 31 M 276 >2000 <0.14 90 38 0.8 140 3.8 13 9.8 182 
18 36 F 53 980 0.05 87 48 2.1 148 4.6 118 202 240 
19 21 F 783 837 0.94 83 20 0.6 138 4.2 6 14 96 
20 30 M 62 421 0.15 80 33 0.8 140 3.8 16 20 80 
21 28 M 63 439 0.14 89 26 0.9 138 4.5 28 18 142 
22 35 M 117 720 0.16 94 33 0.7 140 4.4 62 89 212 
23 41 M 16 570 0.03 102 52 1.9 142 3.6 137 143 495 
24 40 M 83 444 0.19 78 32 1 140 4.8 12 18 120 
25 27 F 553 1760 0.3 84 26 0.9 135 5.1 8 12 80 
26 32 M 123 656 0.19 90 25 0.8 138 3.9 28 13 96 
27 30 F 195 412 0.47 78 28 0.9 136 4.1 4 15.6 108 
28 30 F 183 1315 0.13 92 26 0.9 138 4 68 110 258 
29 33 F 182 918 0.19 80 22 0.6 139 3.8 22 18 172 
 30 30 F 112 566 0.22 86 38 0.9 136 3.5 15 21 135 
31 43 F 196 786 0.25 90 16 0.7 140 3.6 18 9.1 112 
32 38 M 562 790 0.71 84 20 0.9 136 4.1 4 17 128 
33 35 M 1046 826 1.27 76 28 1.1 135 3.9 1.7 8 88 
34 35 F 18 225 0.08 87 48 2.2 138 3.6 110 115 700 
35 38 M 579 1179 0.49 91 32 1 136 3.6 19 23 186 
36 45 F 42 1076 0.04 98 28 0.8 139 3.8 24 28 210 
37 50 F 104 379 0.27 105 18 1.1 138 4 22 16 156 
38 35 M 60 463 0.13 88 48 1,8 138 4.4 160 299 640 
39 30 M 198 407 0.49 92 20 0.9 135 4 14 20 168 
40 34 M 147 426 0.35 80 26 0.8 136 4.2 5 10 112 
41 34 M 602 1366 0.44 76 22 1.2 136 4.5 6 18 128 
42 32 M 356 815 0.44 88 32 1 141 3.6 8 14 112 
43 21 M 47 922 0.05 82 22 0.8 143 4.4 44 36 156 
44 36 M 394 >2000 <0.35 85 28 0.8 138 4.2 6 16 190 
45 37 M 212 634 0.33 81 26 0.9 148 4.3 18 26 126 
46 44 F 45 295 0.15 79 26 0.8 138 3.2 38 52 186 
47 35 M 292 788 0.37 92 18 1.2 142 3.5 20 24 192 
48 33 M 695 1383 0.50 88 23 0.9 138 3.9 26 11 148 
49 30 M 171 1673 0.1O 93 42 1.5 138 3.8 48 62 216 
50 23 M 291 864 0.34 80 32 0.8 132 4.6 16 24 176 
51 37 M 29 500 0.06 86 38 1.9 142 5.2 84 122 300 
52 30 F 252 1191 0.21 91 24 0.9 146 4.2 26 19 165 
53 28 F 32 500 0.06 79 52 1.7 143 4.8 58 116 456 
54 30 M 721 1290 0.56 80 23 0.6 143 3.8 8 12 86 
55 27 F 311 978 0.32 94 28 1.1 134 3.6 12 18 134 
56 29 F 309 >2000 <0.15 80 44 1.9 145 4.5 94 64 325 
57 27 F 528 1841 0.28 96 24 0.9 136 4.5 10 14 80 
58 43 M 233 1318 0.18 92 36 1.4 144 3.9 74 40 215 
59 32 F 40 687 0.06 87 38 1.3 137 3.6 18 20 155 
60 32 F 224 490 0.5 90 24 1.2 138 4 14 9 75 
 
 CONTROLS 
S.NO AGE SEX SUGAR UREA CREATININE NA+ 
 
CL- MICRO  
ALBUMIN 
URINE 
AL/CR 
RATIO 
24 HRS 
URINE 
PROTEIN 
1 33 M 88 22 0.8 138 4.3 1.25 10.5 78 
2 28 M 90 24 0.9 136 3.8 <2.25 9.85 92 
3 38 F 78 32 0.9 144 4.5 <2.25 11 86 
4 42 F 95 28 0.7 139 4.6 1.85 9.8 96 
5 26 M 98 26 0.9 146 4.1 2.5 12.6 102 
6 36 M 79 20 0.8 138 3.6 2.5 11.7 90 
7 44 M 82 28 0.9 140 4.1 12 <13 112 
8 35 F 86 26 1 142 4.5 2.5 10.5 82 
9 28 F 93 24 0.7 138 4.3 1.25 11.5 90 
10 22 M 80 22 0.9 136 3.8 2.5 8 88 
11 26 F 92 30 1.1 148 4.7 8 11.2 106 
12 31 F 78 26 0.7 143 3.9 2.5 10.1 98 
13 26 M 100 28 0.9 139 4.4 4 11.5 80 
14 39 M 94 20 1 141 4.2 1.05 8.2 92 
15 25 F 99 22 0.8 138 4.6 2.5 10.2 88 
16 30 F 87 18 0.9 140 4 1.05 10.8 92 
17 36 M 83 28 0.8 139 4.3 2.5 6 102 
18 40 F 80 18 0.7 145 4.1 2 8 82 
19 32 M 92 22 0.8 136 3.9 1.25 11 112 
20 26 F 97 28 1.1 138 3.7 2.5 12 90 
  
